News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
121,748 Results
Type
Article (7294)
Company Profile (56)
Press Release (114398)
Section
Business (38872)
Career Advice (95)
Deals (6044)
Drug Delivery (8)
Drug Development (23716)
Employer Resources (13)
FDA (3066)
Job Trends (3603)
News (69661)
Policy (4702)
Tag
Academia (330)
Adcomms (9)
Africa (91)
Alabama (18)
Alliances (11293)
Alzheimer's disease (111)
Antibody-drug conjugate (ADC) (40)
Approvals (3053)
Artificial intelligence (14)
Asia (10289)
Australia (1363)
Bankruptcy (53)
Best Places to Work (3152)
Biosimilars (14)
Biotechnology (48)
Breast cancer (21)
C2C Services and Suppliers (7849)
California (414)
Canada (157)
Cancer (205)
Career advice (82)
CAR-T (24)
Cell therapy (41)
China (36)
Clinical research (18983)
Collaboration (32)
Colorado (11)
Connecticut (16)
COVID-19 (298)
Data (43)
Delaware (13)
Diagnostics (1232)
Earnings (12667)
Employer resources (13)
Europe (19165)
Events (22362)
Executive appointments (30)
FDA (3095)
Florida (44)
Funding (25)
Gene therapy (11)
GLP-1 (91)
Government (478)
Healthcare (4082)
Hotbed/Location (84699)
Illinois (34)
Indiana (17)
Infectious disease (304)
Inflammatory bowel disease (19)
Interviews (13)
IPO (2968)
Job creations (491)
Job search strategy (77)
Layoffs (106)
Legal (493)
Liver cancer (28)
Lung cancer (54)
Maryland (89)
Massachusetts (333)
Medical device (890)
Medtech (890)
Mergers & acquisitions (3051)
Metabolic disorders (18)
Michigan (15)
Minnesota (44)
Neuroscience (126)
New Jersey (71)
New York (112)
NextGen Class of 2024 (976)
Non-profit (523)
North Carolina (114)
Northern California (208)
Obesity (9)
Ohio (22)
Opinion (24)
Ovarian cancer (12)
Pancreatic cancer (12)
Pennsylvania (69)
People (12651)
Pharmaceutical (10)
Phase I (7109)
Phase II (8054)
Phase III (6096)
Pipeline (31)
Postmarket research (472)
Preclinical (2192)
Prostate cancer (10)
Real estate (772)
Regulatory (3910)
Research institute (671)
Resumes & cover letters (11)
Series A (11)
South America (120)
Southern California (175)
Startups (763)
Texas (44)
United States (1555)
Utah (9)
Vaccines (68)
Washington State (46)
Date
Today (23)
Last 7 days (106)
Last 30 days (626)
Last 365 days (10347)
2024 (6507)
2023 (10838)
2022 (13288)
2021 (13403)
2020 (11203)
2019 (8804)
2018 (6538)
2017 (7275)
2016 (6417)
2015 (7106)
2014 (4664)
2013 (3214)
2012 (3557)
2011 (3469)
2010 (3141)
121,748 Results for "rain oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Pathos AI Completes Acquisition of Rain Oncology
Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc.
January 26, 2024
·
4 min read
Biotech Bay
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
Rain Oncology, Inc. confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs.
October 16, 2023
·
2 min read
Business
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
Rain Oncology Inc. reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations.
November 9, 2023
·
4 min read
Deals
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
Rain Oncology Inc., announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share.
December 13, 2023
·
8 min read
Business
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rain Oncology Inc., reports financial results for the second quarter ended June 30, 2023, and provides a corporate update.
August 10, 2023
·
7 min read
Business
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023.
July 26, 2023
·
1 min read
Biotech Bay
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
Rain Oncology Inc., a clinical stage company developing precision oncology therapeutics announced an update to its clinical strategy for milademetan, its small molecule inhibitor of the MDM2-p53 complex, to optimize Company resources.
May 30, 2023
·
5 min read
Deals
Grab an umbrella, it’s raining IPOs!
This week, Lori, Greg and Tyler discuss the first surge of IPO activity this year plus gene therapy pricing,
January 23, 2024
·
1 min read
·
Lori Ellis
Biotech Bay
Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting
Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain) today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.
November 17, 2022
·
1 min read
Biotech Bay
Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference
Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright’s 3rd Annual Precision Oncology Conference on November 14, 2022.
November 14, 2022
·
1 min read
1 of 12,175
Next